Atomized Labs

Our Platform ?

Atomized Lab's platform has been desigend to treat a range of lung disorders, including non-small cell lung cancer and COPD. The platform is designed to have the following features:

Learn More

Low Shear Delivery

Our technology can deliver fragile molecules, such as immunotherapy biologics, with little shearing or denaturing.

Digigal Breath Actuation

Our device has been designed to sense when the user begins to inhale and automatically eject the prescribed dose of drug without timing problems and without propellants.

High Respirable Friction

Our technology produces aerosols with very high respirable fractions of up to 90%, allowing for high concentrations of a drug to be delivered directly to the lungs.

Therapeutic Treatments for Lung Conditions

Atomized Labs is a early stage med-tech company focused on the advancment of inhaled respiratory therapeutics. With a bold vision, advanced aerosol technology, and strategic partnerships, Atomized brings new approaches and innovations to respiratory health that will significantly improve the existing standard-of-care and produce a positive impact on the health and well-being of the global community.

Ease- of - Use

The device does not require shaking, priming, or marked physical pressure to operate, making it easy for children and seniors to use. The device has been designed with the ability to deliver prompts, via voice or tones, which we believe may help patients use the device correctly.

Dose Verification

Sensors in the device will be able to verify that the drug or medicine has indeed been inhaled.

Improved Patient Compliance

Data will be wirelessly captured and released via Bluetooth™ to the cloud for use by patients and physicians. The rapid feedback to physicians is expected to greatly increase the degree to which patients comply with their prescribed treatments (a key source of treatment failure).

Technology

Atomized Lab's provides new treatments for respiratory diseases through the inhalation of therapeutic aerosols using its proprietary Tri-Respi™ technology. Atomized's echnology delivers solid-phase fine particle aerosols generated from viscous solutions of high molecular weight drugs and suspensions. It can also be used to deliver high concentrations of sparsely soluble compounds. These inhaled therapeutics are delivered at a preselected size and at high dose rates, minimizing treatment times and improving clinical outcomes. Atomized's Tri-Respi is a patented new class of aerosol delivery system. In this system, a large liquid aerosol is generated with a low-shear nozzle, dried, concentrated and delivered on demand. The dose rates are 5 to 30 times higher than current nebulizer technologies. Tri-Respi extends the range of molecule, nanoparticles and organelles that can be aerosolized to form fine particle aerosols. These include, antibodies, antibody drug conjugates, fusion proteins, surfactants, oligonucleotides, cellular organelles, viruses and multi-walled carbon nanotubes (MWCNT's). Atomized's proprietary aerosol generation technologies are also applicable to the generation of aerosols of cells and cellular organelles. Tri-Respi can also be used to generate nanoparticles and non-flammable vapors.

Improved Patient Compliance

High Dose Confidence Modes

he device designed to include a High Dose Confidence (HDC) mode. In HDC mode, the device will calculate the dose left to be inhaled if the patient does not complete their inhalation over a fixed time. In the HDC mode, the device measures the remaining dose and issues the voice command “Please inhale again to complete your dose” and continues to do so for up to three times if the patient does not fully complete their dose. If a complete dose cannot be given, that information is sent to the cloud via a smartphone app where the doctor can see the missed doses along with other compliance data.

Treatment of Lung Diseases by Aerosol Inhalation

Acute respiratory distress syndrome (ARDS) afflicts 10% of patients in intensive care (>200,000) with 40-60% mortality. Within 48 hours of a precipitating insult, patients develop multifocal airway collapse, edema and hypoxemia; each caused or aggravated by defective surfactant and its continued inflammation-induced degradation.

Surfactant Aerosol therapy for RDS

Of the 15 million premature babies born around the world, one million will die annually within the first month of life, and many of the 14 million survivors are faced with a lifetime of serious health complications. Respiratory distress syndrome, RDS, is the single most important cause of mortality and morbidity in preterm infants. In the case of neonatal respiratory distress, the surfactant deficiency is due to the lack of surfactant production in infants born prematurely and, as expected, the severity increases inversely proportional to gestational age.

Tri-Respi

erosols 2 to 4 micron MMAD can be delivered at rates of up to 30 fold higher than current nebulizers resulting in far shorter treatment times.

Pure protein respirable aerosols can be delivered up to 4 mg/s and 15 mg/l

High payloads of up to 2 g can be delivered.

Respirable aerosols of higher molecular weight compounds and more viscous solutions, > 34 cP, can be generated with SUPRAER than with other nebulizers

Atomized Labs, LLC

Modi nostrum vel laborum. Porro fugit error sit minus sapiente sit aspernatur

Get In Touch

Magnam dolores commodi suscipit. Necessitatibus eius consequatur ex aliquid fuga eum quidem. Sit sint consectetur velit. Quisquam quos quisquam cupiditate. Et nemo qui impedit suscipit alias ea. Quia fugiat sit in iste officiis commodi quidem hic quas.

Your appointment request has been sent successfully. Thank you!

A New Delivery Platform

Paired with a mobile app, the device is capable of delivering real-time dose verification data. Dose verification is important for health systems, doctors and patients who are concerned with drug use and compliance.

A novel part of Atomizeds's digital soft mist device is its ability to deliver different sized droplets of medicine via its droplet ejector technology. This will allow the device to potentially target different areas of the lung

Management Team

With overy 30 years combined experience n inhalation technology, Atomized Laboratoizes is the future of inhaled medications and inhalation technology: